Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naquotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 10/20 | 0.95 |
| ▸ | RET | P07949 | 9/20 | 0.59 |
| ▸ | ROS1 | P08922 | 9/20 | 0.59 |
| ▸ | FLT3 | P36888 | 9/20 | 0.59 |
| ▸ | EML4 | Q9HC35 | 8/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.59 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | BUB1 | O43683 | 1/20 | 0.48 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.48 |
| ▸ | STK16 | O75716 | 1/20 | 0.48 |
| ▸ | STK10 | O94804 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | LATS1 | O95835 | 1/20 | 0.48 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naquotinib SCHEMBL18687011 | 1.00 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL29355759 | 0.97 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL16196078 | 0.97 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL19921009 | 0.97 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16195821 | 0.94 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207133 | 0.94 | EGFR (0.93) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16196142 | 0.92 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207004 | 0.92 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16258225 | 0.92 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207170 | 0.90 | EGFR (0.87) | EGFRRETROS1FLT3EML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| CN-120091813-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4531846-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2024-04-11 | — | — | US | claimed |
| CN-117729923-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4288057-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023235356-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-120091813-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4531846-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4171518-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11433022-B2 | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | DUSP6, SOS1, DUSP1 | EGFR 20/4885RET 39/4885ROS1 32/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | EGFR 2354/4885RET 3412/4885ROS1 2306/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | EGFR 3246/4885RET 4264/4885ROS1 4534/4885 |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | EGFR 24/4885RET 57/4885ROS1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.